ENSIKLOPEDIA

Tekan Enter untuk memulai pencarian cepat.

Kembali ke Ensiklopedia Arsip Wikipedia Indonesia

ATC code J05

Pharmaceutical drug classification

ATC code J: Antiinfectives for systemic use
J01 Antibacterials for systemic use J02 Antimycotics for systemic use J04 Antimycobacterials J05 Antivirals for systemic use
Human only
J06 Immune sera and immunoglobulins J07 Vaccines
ATCvet only
QJ51 Antibacterials for intramammary use QJ54 Antimycobacterials for intramammary use
Other ATC codes
A B C D G H QI J L M N P R S V

ATC code J05 Antivirals for systemic use is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.^[1]^[2]^[3] Subgroup J05 is part of the anatomical group J Antiinfectives for systemic use.^[4]

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QJ05.^[5]
National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version.

J05A Direct acting antiviral drugs

J05AP58 Daclatasvir, asunaprevir and beclabuvir

J05AR Antivirals for treatment of HIV infections, combinations

J05AR01 Zidovudine and lamivudine

J05AR02 Lamivudine and abacavir

J05AR03 Tenofovir disoproxil and emtricitabine

J05AR04 Zidovudine, lamivudine and abacavir

J05AR05 Zidovudine, lamivudine and nevirapine

J05AR06 Emtricitabine, tenofovir disoproxil and efavirenz

J05AR07 Stavudine, lamivudine and nevirapine

J05AR08 Emtricitabine, tenofovir disoproxil and rilpivirine

J05AR09 Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat

J05AR10 Lopinavir and ritonavir

J05AR11 Lamivudine, tenofovir disoproxil and efavirenz

J05AR12 Lamivudine and tenofovir disoproxil

J05AR13 Lamivudine, abacavir and dolutegravir

J05AR14 Darunavir and cobicistat

J05AR15 Atazanavir and cobicistat

J05AR16 Lamivudine and raltegravir

J05AR17 Emtricitabine and tenofovir alafenamide

J05AR18 Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat

J05AR19 Emtricitabine, tenofovir alafenamide and rilpivirine

J05AR20 Emtricitabine, tenofovir alafenamide and bictegravir

J05AR21 Dolutegravir and rilpivirine

J05AR22 Emtricitabine, tenofovir alafenamide, darunavir and cobicistat

J05AR23 Atazanavir and ritonavir

J05AR24 Lamivudine, tenofovir disoproxil and doravirine

J05AR25 Lamivudine and dolutegravir

J05AR26 Darunavir and ritonavir

J05AR27 Lamivudine, tenofovir disoproxil and dolutegravir

J05AR28 Stavudine and lamivudine

J05AR29 Emtricitabine, tenofovir alafenamide and dolutegravir

J05AX Other antivirals

J05AX01 Moroxydine

J05AX02 Lysozyme

J05AX05 Inosine pranobex

J05AX06 Pleconaril

J05AX07 Enfuvirtide

J05AX09 Maraviroc

J05AX10 Maribavir

J05AX12 Dolutegravir

J05AX13 Umifenovir

J05AX17 Enisamium iodide

J05AX18 Letermovir

J05AX19 Tilorone

J05AX21 Pentanedioic acid imidazolyl ethanamide

J05AX23 Ibalizumab

J05AX24 Tecovirimat

J05AX25 Baloxavir marboxil

J05AX26 Amenamevir

J05AX27 Favipiravir

J05AX28 Bulevirtide

J05AX29 Fostemsavir

J05AX31 Lenacapavir

J05AX32 Riamilovir

J05AX33 Labuvirtide

References

↑ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
↑ "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
↑ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
↑ "ATC/DDD Index 2022: code J05". WHO Collaborating Centre for Drug Statistics Methodology.
↑ "ATCvet Index 2022: code QJ05". WHO Collaborating Centre for Drug Statistics Methodology.

DNA virus antivirals (primarily J05, also S01AD and D06BB)

Baltimore I

Herpesvirus

DNA-synthesis
inhibitor

TK activated

Purine analogue	guanine (Aciclovir^#/Valaciclovir Ganciclovir/Valganciclovir^# Penciclovir/Famciclovir) adenine (Vidarabine)
Pyrimidine analogue	uridine (Idoxuridine Trifluridine (+tipiracil) Edoxudine) thymine Brivudine FV-100^† Sorivudine^‡

Not TK activated

Foscarnet

Other

Amenamevir
Docosanol
Letermovir
Maribavir
early protein (Fomivirsen^‡)
Tromantadine

HPV/MC

Imiquimod/Resiquimod
Podophyllotoxin^#

Vaccinia

assembly: Rifampicin

Poxviridae

Methisazone
Tecovirimat

Hepatitis B (VII)

Nucleoside analogues/NARTIs: Entecavir^#
Lamivudine
Lobucavir^†
Telbivudine
Clevudine

Nucleotide analogues/NtRTIs: Adefovir
Tenofovir disoproxil
Tenofovir alafenamide

Multiple/general

Nucleic acid inhibitors	Cidofovir Brincidofovir
Interferon	Interferon alfa 2b Peginterferon alfa-2a^#
Multiple/unknown	Filociclovir^† Ribavirin^#/Taribavirin^† Moroxydine

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

RNA virus antivirals (primarily J05, also S01AD and D06BB)

Hepatitis C

NS3/4A protease inhibitors (–previr)	Asunaprevir Boceprevir^‡ Ciluprevir^§ Danoprevir^† Faldaprevir^‡ Glecaprevir Grazoprevir Narlaprevir Paritaprevir Simeprevir Sovaprevir^† Telaprevir^‡ Vaniprevir Vedroprevir^§ Voxilaprevir
NS5A inhibitors (–asvir)	Coblopasvir Daclatasvir^# Elbasvir Ledipasvir Netanasvir Odalasvir^† Ombitasvir Pibrentasvir Ravidasvir^† Ruzasvir^† Samatasvir^† Velpatasvir
NS5B RNA polymerase inhibitors (–buvir)	Beclabuvir^† Bemnifosbuvir^† Dasabuvir^# Deleobuvir^§ Encofosbuvir Filibuvir^§ GS-6620^§ IDX-184^§ Setrobuvir^§ Sofosbuvir^# Tegobuvir^§ TMC-647055^§ Radalbuvir^† Uprifosbuvir^†
Combination drugs	Elbasvir/grazoprevir Glecaprevir/pibrentasvir Ledipasvir/sofosbuvir^# Ombitasvir/paritaprevir/ritonavir^# Sofosbuvir/daclatasvir Sofosbuvir/velpatasvir^# Sofosbuvir/velpatasvir/voxilaprevir

Hepatitis D

Bulevirtide

Picornavirus

viral entry: Pleconaril^†

Anti-influenza agents

Baloxavir marboxil
Onradivir
Pimodivir^†
Umifenovir

adamantane derivatives/M2 inhibitors (Adapromine
Amantadine
Rimantadine)

neuraminidase inhibitors/release phase (Oseltamivir^#
Zanamivir
Peramivir, Laninamivir^†)

Multiple/general

Interferon	Interferon alfa 2b Peginterferon alfa-2a^# Peginterferon alfa-2b^#
3CL protease inhibitors (–trelvir)	Atilotrelvir Ensitrelvir^† Ibuzatrelvir Leritrelvir Lufotrelvir Nirmatrelvir^† (+ritonavir)^† Rupintrivir Simnotrelvir (+ritonavir^†)
RNA pol inhibitors	CMX521^§ Deuremidevir^† Favipiravir Galidesivir^† GS-441524^§ Remdesivir MK-608^§ Mericitabine^† Molnupiravir NITD008^§ Ribavirin^# Taribavirin^† Triazavirin Valopicitabine^†
Multiple/Unknown/Other	EICAR^§ Merimepodib^§ Moroxydine Presatovir^†

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)

Capsid inhibitors

Lenacapavir (LEN)

Entry/fusion inhibitors
(Discovery and development)

gp41 (Enfuvirtide (ENF, T-20))^◊
CCR5 (Maraviroc (MVC)
Vicriviroc^†, Cenicriviroc^†, Leronlimab^†)
CD4 (Ibalizumab (IBA), Semzuvolimab^§)
gp120 (Fostemsavir (FTR))

Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))

Bictegravir (BIC)
Cabotegravir (CAB)
Dolutegravir (DTG)^#
Elvitegravir (EVG)
Raltegravir (RAL)^#
BI 224436^†
MK-2048^†

Maturation inhibitors

Bevirimat^†
BMS-955176^§
Fipravirimat^§

Protease Inhibitors (PI)
(Discovery and development)

1^st generation	Amprenavir (APV)^‡ Fosamprenavir (FPV) Indinavir (IDV)^◊ Lopinavir (LPV) Nelfinavir (NFV)^◊ Ritonavir (RTV)^# Saquinavir (SQV)^◊
2^nd generation	Atazanavir (ATV)°^# Darunavir (DRV)°^# Tipranavir (TPV)^◊ TMC-310911^§

Reverse-transcriptase
inhibitors (RTIs)

Nucleoside and
nucleotide (NRTI)

Nucleoside analogues/NRTIs: Abacavir (ABC)^#
Didanosine (ddI)^◊
Emtricitabine (FTC)
Islatravir (ISL)
Lamivudine (3TC)^#
Stavudine (d4T)^◊
Zalcitabine (ddC)^‡
Zidovudine (AZT, ZDV)^#
Amdoxovir^†
Apricitabine^†
Censavudine^†
Elvucitabine^†
Racivir^†
Stampidine^†

Nucleotide analogues/NtRTIs: Tenofovir disoproxil (TDF)^#
Tenofovir alafenamide (TAF)

Non-nucleoside (NNRTI)
(Discovery and development)

1^st generation	Efavirenz (EFV)^# Nevirapine (NVP)^# Delavirdine (DLV)^‡
2^nd generation	diarylpyrimidines Dapivirine (DPV) Etravirine (ETR) Rilpivirine (RPV) Doravirine (DOR) Elsulfavirine (ESV)

Combined formulations

Abacavir/lamivudine^#
Abacavir/dolutegravir/lamivudine°
Abacavir/lamivudine/zidovudine
Atazanavir/cobicistat
Bictegravir/emtricitabine/tenofovir alafenamide°
Cabotegravir/rilpivirine
Darunavir/cobicistat
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide°
Dolutegravir/emtricitabine/tenofovir alafenamide
Dolutegravir/lamivudine°
Dolutegravir/lamivudine/tenofovir alafenamide°
Dolutegravir/lamivudine/tenofovir disoproxil°^#
Dolutegravir/rilpivirine
Doravirine/islatravir
Doravirine/lamivudine/tenofovir disoproxil
Efavirenz/emtricitabine/tenofovir disoproxil^#
Efavirenz/lamivudine/tenofovir disoproxil^#
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
Emtricitabine/tenofovir alafenamide
Emtricitabine/rilpivirine/tenofovir alafenamide
Emtricitabine/rilpivirine/tenofovir disoproxil
Emtricitabine/tenofovir disoproxil^#
Lamivudine/nevirapine/stavudine
Lamivudine/nevirapine/zidovudine
Lamivudine/raltegravir
Lamivudine/tenofovir disoproxil^#
Lamivudine/zidovudine^#
Lopinavir/ritonavir^#

Pharmacokinetic boosters

Cobicistat (c)
Ritonavir (r)^#

Experimental agents

Uncoating inhibitors	TRIM5alpha (gene)
Transcription inhibitors	Tat antagonists
Translation inhibitors	Trichosanthin
BNAbs	Elipovimab
Other	Abzyme BIT225^† Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) Foscarnet Fosdevirine^† Griffithsin Hydroxycarbamide KP-1461^† Miltefosine North-methanocarbathymidine Portmanteau inhibitors Scytovirin Seliciclib^† Synergistic enhancers Tre recombinase Zinc finger protein transcription factor
Failed agents	Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine Lodenosine Loviride Mozenavir Palinavir Telinavir

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

°DHHS recommended initial regimen options. ^◊Formerly or rarely used agent.

Sumber data: id.wikipedia.org via REST API v1

J05A Direct acting antiviral drugs

J05AA Thiosemicarbazones

J05AB Nucleosides and nucleotides excluding reverse transcriptase inhibitors

J05AC Cyclic amines

J05AD Phosphonic acid derivatives

J05AE Protease inhibitors

J05AF Nucleoside and nucleotide reverse-transcriptase inhibitors

J05AG Non-nucleoside reverse-transcriptase inhibitors

J05AH Neuraminidase inhibitors

J05AJ Integrase inhibitors

J05AP Antivirals for treatment of HCV infections

J05AR Antivirals for treatment of HIV infections, combinations

J05AX Other antivirals

References